Decoy Therapeutics is trading at $3.98 (up 6.4%) after announcing that a D-MAV candidate demonstrated in vitro activity against the wild-type Ebola Zaire virus.
- The results validate the company's D-MAV platform beyond coronaviruses, demonstrating the potential for broader antiviral applications.
- Decoy has initiated an exploratory program to further investigate this Ebola-related opportunity following the successful validation.
- The stock is seeing a company-specific lift despite broader weakness in the biotech sector as investors react to the platform's expansion potential.